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nsulin resistance is a key feature of type 2 diabetes,
and the strong association between fat oversupply
and defective insulin action in target tissues, espe-
cially skeletal muscle and liver, has motivated the
search for intracellular lipid mediators that can interfere
with insulin signaling and glucose homeostasis. Two of the
best-studied candidates are diacylglycerol (DAG) and cer-
amide (1–3), to the extent that the tissue levels of these
intermediate species are now routinely measured in mod-
els of insulin resistance and in human studies. Correlative
evidence for their roles has accumulated over the last
10–15 years, but unfortunately, there are now several
conﬂicting reports concerning the relative importance of
these molecules (4–7). To resolve this situation, it is
necessary to go beyond descriptive studies in order to
address causation and elucidate the mechanisms involved.
In the case of ceramide, the inhibitor myriocin is prov-
ing to be a useful tool. This fungal metabolite is a potent
and speciﬁc blocker of serine palmitoyltransferase (SPT),
the ﬁrst enzyme in the pathway of de novo ceramide
synthesis (8). By reducing the condensation of serine with
palmitoyl-CoA to form 3-ketosphinganine (Fig. 1), the
inhibitor is able to decrease ceramide synthesis without
elevating intermediates such as sphinganine, which are
upstream of ceramide formation and also have biological
effects (9). Myriocin treatment of rats infused with differ-
ent lipid cocktails for 6 h to induce insulin resistance in an
acute fashion demonstrated that a reduction in ceramide
accumulation in skeletal muscle could prevent defects in
glucose disposal (10). Longer-term administration of the
inhibitor was also able to improve glucose tolerance in
genetically obese Zucker diabetic fatty (ZDF) rats and
fat-fed mice. Finally, this study also supported the conclu-
sion, drawn from in vitro work (11), that saturated fatty
acids contribute to ceramide accumulation, whereas un-
saturated fatty acids induce insulin resistance by ceram-
ide-independent mechanisms involving, for example, DAG-
activated protein kinase C (PKC) isoforms or phosphatidic
acid (1,12).
Mechanistic investigations carried out in cell models
have elucidated direct effects of ceramide on insulin
signaling components, especially the inhibition of Akt
through activation of phosphatases or atypical PKC,
which could account for the induction of insulin resistance
(13,14). Recent reports of the use of myriocin to reverse
preexisting insulin resistance in vivo, especially in models
of diet-induced obesity, 1) indicate a broader role for
ceramide accumulation in the development of insulin
resistance and the metabolic syndrome, and 2) suggest
that this may be a clinically useful approach (15–17). In
this issue of Diabetes, Ussher et al. (16) report the effects
of myriocin treatment on glucose homeostasis in mice fed
a high-fat diet for 12 weeks. In addition to substantiating
the role of ceramide in muscle insulin resistance, they
provide some new insights into the actions of the lipid
intermediate on glucose and lipid metabolism in vivo.
Myriocin, administered for 2 weeks, improved glucose and
insulin tolerance and also restored insulin signal transduc-
tion in skeletal muscle at the level of Akt, as might be
predicted from its effects in vitro and upon acute lipid
infusion.
More unexpectedly, the inhibitor also reversed fat diet–
induced defects in whole-body oxygen consumption and
mitochondrial function. Furthermore, the authors were
able to link ceramide accumulation with the contention
that incomplete fatty acid oxidation contributes to insulin
resistance (18). Myriocin reduced the accumulation of
short-chain acylcarnitine esters and increased muscle tri-
glyceride accumulation, suggesting that fatty acid oxida-
tion was inhibited, whereas glucose metabolism was
improved. The mechanistic link between ceramide accu-
mulation and mitochondrial dysfunction was not explored
but could involve processes such as the generation of
reactive oxygen species or an increase in membrane
permeability (rev. in [19]). The in vivo situation is likely to
be complex, involving interplay between different meta-
bolic tissues. Yang et al. (15) have also recently examined
the effects of myriocin treatment in dietary and genetic
models of obesity, reporting beneﬁcial changes in the
regulation of energy expenditure in liver and adipose,
linked with the expression of suppressor of cytokine
signaling-3 and uncoupling protein-3. It is possible that the
improvements in insulin signaling reported in each study
were at least in part secondary to the action of myriocin on
fuel metabolism (Fig. 1).
The effects of myriocin may not, however, be limited to
direct actions on ceramide accumulation in insulin target
tissues. Ceramide-dependent pathways regulate several
aspects of the immune response (20), and the inhibitor
possesses potent immunosuppressant activity in vivo (21).
Chronic inﬂammation is associated with insulin resis-
tance, especially under conditions of long-term fat over-
supply (22), and it is therefore likely that myriocin has
indirect effects on muscle insulin action by reducing the
activation of macrophages either locally or in adipose
tissue, to reduce the release of inhibitory cytokines (G.I.
Lancaster and M.A. Febbraio, personal communication).
Ussher et al. (16) did not observe any increase in the
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activated protein kinase or c-Jun NH2-terminal kinase in
muscle in their dietary model, although the possibility
remains that myriocin inhibited inﬂammatory mechanisms
elsewhere that impinged on muscle insulin action. Indeed,
Yang et al. (15) reported that the inhibitor reduced the
release of plasminogen activator inhibitor-1 and monocyte
chemoattractant protein-1 from adipose tissue. Further-
more, the anti-inﬂammatory agent lisofylline also reduces
muscle ceramide accumulation and improves glucose tol-
erance in fat-fed mice (17), indicating that disruption of
the cycle between inﬂammation and ceramide production,
by means other than direct inhibition of ceramide synthe-
sis, can be beneﬁcial for glucose homeostasis (Fig. 1).
Ussher et al. further examined ceramide accumulation
and the effects of myriocin treatment in muscle from db/db
mice. No increase in ceramide was observed in untreated
db/db mice compared with db/ controls, whereas cer-
amide levels were reduced and glucose homeostasis was
improved by administration of myriocin. This indicates
that the relationship between ceramide accumulation and
insulin action can be less direct, and the authors suggest
that their data are consistent with the view that ceramide
metabolites such as glucosylceramides can also play a role
in the generation of insulin resistance (3). It has become
apparent that the cycling between ceramide and complex
sphingolipids through a salvage pathway, which involves
hydrolysis to sphingosine and reacylation (Fig. 1), is at
least as important in ceramide action as the de novo
synthetic route (23). In each case, both saturated and
unsaturated fatty acids of varying chain lengths are incor-
porated by ceramide synthases (CerS1-6, encoded by the
longevity assurance homologue [LASS] genes) to (re)gen-
erate the ceramide sidechain (23) (Fig. 1). An important
corollary is that the use of the saturated fatty acyl-CoA
derived from palmitate by SPT to form the sphingoid
backbone is rate-limiting only for de novo synthesis of
ceramide (Fig. 1). Thus, in contrast to the ﬁndings from
acute lipid infusions (10), ceramides can accumulate upon
the oversupply of either saturated or unsaturated fatty
acids in the longer term (17), most likely as a consequence
of salvage pathway activity. Through their speciﬁcity and
level of expression, LASS isoforms determine the array of
ceramide species with differing acyl sidechains that can be
detected (15,17). Changes in the expression of CerS1, the
most abundant isoform in skeletal muscle, are associated
with alterations in ceramide levels and glucose tolerance
in muscle from fat-fed mice (17). An important next step in
the understanding of ceramide action is therefore to
determine whether there are speciﬁc roles for particular
species of ceramide and the corresponding complex sphin-
golipids. Targeting CerS isoforms rather than SPT may in
fact represent a better therapeutic strategy to reduce
ceramide accumulation given the potential for speciﬁcity
and the ability to inhibit the salvage pathway as well as de
novo synthesis.
Finally, the continued controversy regarding the relative
importance of ceramide and DAG in the generation of
lipid-induced insulin resistance remains to be resolved.
Although it appears that lipid composition is a key factor
in vitro and in acute in vivo models, it is likely that further
explanations are required to reconcile the discrepancies
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FIG. 1. Roles of SPT, CerS, and sphingomyelinase (SMase) in the metabolism of ceramides. De novo synthesis of ceramide is initiated by the
condensation of serine with palmitoyl-CoA by SPT to generate the sphingoid backbone. A range of saturated and unsaturated fatty acids
(acyl-CoA) can be subsequently incorporated by CerS (LASS) isoforms to form the ceramide sidechain. The salvage pathway, responsible for the
cycling between ceramide and complex sphingolipids, also involves CerS activity and can also promote ceramide accumulation upon fatty acid
oversupply. See references (9) and (24) for further details of sphingolipid metabolism. Inﬂammation can promote ceramide release from
sphingomyelin through the activation of SMase by cytokines. Studies in intact cells and in vivo suggest that ceramide (and possibly also complex
sphingolipids) can affect insulin action at least in part by inducing further stress signaling and mitochondrial dysfunction as well as by directly
inhibiting insulin signal transduction.
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genetic models and in human studies. As well as the
analysis of individual ceramide and DAG species, investi-
gation of the cellular locations of these inhibitory media-
tors by subcellular fractionation may shed more light on
this issue. For example, total DAG levels, comprising both
DAG released at the plasma membrane and also that
synthesized at the endoplasmic reticulum, mitochondria,
and lipid droplets (19), may not always reﬂect the accu-
mulation of the pool(s) of this intermediate which can
promote PKC activation. Similarly, differential intracellu-
lar distribution of CerS isoforms is likely to give rise to
pools of ceramide with distinct roles (23).
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